MicroRNA Modulation for Post-Myocardial Infarction Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myocardial infarction and heart failure do not effectively address the post-myocardial infarction remodeling process, which leads to further cardiac damage and potential life-threatening arrhythmias, with no known therapeutic interventions available to manage this aspect of heart disease.
Innovation Solution
Modulation of specific microRNAs (miRNAs) such as let-7 family members, miR-15b, miR-21, miR-199a, and others, through the use of inhibitors or agonists, to regulate their expression or activity in heart cells, thereby treating or preventing myocardial infarction, cardiac remodeling, and heart failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for myocardial infarction are used, then immediate cardiac damage is addressed, but post-myocardial infarction remodeling is not effectively managed leading to further cardiac damage
Solution Approach 1:
The patent segments the treatment approach by identifying and targeting specific microRNAs (such as miR-21, miR-29, miR-1) that are differentially expressed during post-MI remodeling. This allows for stage-specific and mechanism-specific therapeutic intervention, addressing the remodeling process separately from acute infarct management.
Solution Approach 2:
The patent employs parameter changes by modulating microRNA expression levels (upregulating protective miRNAs like miR-29 and downregulating harmful miRNAs like miR-21) to control the remodeling process. This molecular-level parameter adjustment provides a new dimension for therapeutic intervention.
2Device complexity
If no therapeutic intervention is applied to post-MI remodeling, then treatment complexity is low, but fibrosis and arrhythmias increase
Solution Approach 1:
The patent uses microRNAs as intermediary molecules to mediate the therapeutic effect. These small non-coding RNAs serve as intermediaries between the administered therapy and the target genes involved in remodeling, fibrosis, and arrhythmia development, providing a controlled mechanism for disease modification.
Solution Approach 2:
The patent applies preliminary action by intervening in the remodeling process before irreversible damage occurs. By targeting microRNA expression early in the remodeling phase, the therapy prevents the development of severe fibrosis and arrhythmias before they become life-threatening conditions.
3Reliability
If microRNA modulation is implemented, then therapeutic effectiveness improves, but treatment mechanism complexity increases
Solution Approach 1:
The patent extracts and isolates specific microRNA molecules (such as miR-21, miR-29, miR-1) from the complex cellular environment and uses them as discrete therapeutic agents. This extraction approach simplifies the treatment mechanism by focusing on key regulatory molecules rather than attempting to modulate the entire gene expression network.
Data Source
AI summary
The present invention relates to the identification of miRNAs that are involved in heart failure and the process of post-myocardial infarction remodeling in heart tissue. Modulation of these identified miRNAs as a treatment for myocardial infarction, cardiac remodelling, and heart failure is described.